Other Events ·
Matinas BioPharma Holdings, Inc. received a notice from the NYSE American on August 31, 2026, stating it is not in…
MTNBMatinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. received a notice from the NYSE American on August 31, 2026, stating it is not in compliance with continued listing standards requiring stockholders' equity of at least $2.0 million. The company reported stockholders’ equity of $1.8 million as of June 30, 2026, and has incurred losses from continuing operations or net losses in its five most recent fiscal years. This noncompliance relates to Section 1003(a)(i) of the NYSE American Company Guide, adding to existing notices regarding Sections 1003(a)(ii) and (iii). The company submitted a compliance plan on May 4, 2026, which was accepted by the exchange. Matinas has until October 2, 2027, to regain compliance or face delisting proceedings. The notice does not immediately impact trading, which continues under symbol MTNB with a .BC indicator. Matinas BioPharma is a biopharmaceutical company focused on delivering therapies using its lipid nanocrystal platform technology.